Skip to main content
EJNMMI Research
Fig. 3 | EJNMMI Research

Fig. 3

From: Development of a PET/CT molecular radiomics-clinical model to predict thoracic lymph node metastasis of invasive lung adenocarcinoma ≤ 3 cm in diameter

Fig. 3

Evaluation of the performance of the integrated PET/CT molecular radiomics-clinical model. A The nomogram was developed by combining the PET/CT radiomic score and the clinical features of solid composition and location/body part (1, 2, 3, 4, 5 represent the upper lobe, middle lobe, and lower lobe of the right lung and the upper lobe and lower lobe of the left lung, respectively). B Calibration curve with the Hosmer–Lemeshow test of the nomogram in the training cohort (left panel) and test cohort (right panel). The calibration curve shows the calibration of the model in terms of the consistency between the predicted risk of thoracic LNM and the real observed thoracic LNM status. The x-axis represents the predicted risk of thoracic LNM, and the y-axis represents the real thoracic LNM status. C Decision curve analysis of the nomograms. The y-axis measures the standardized net benefit. The dark line represents the PET/CT molecular radiomics-clinical nomogram model, the red line represents the clinical features nomogram, the grey line represents the assumption that all patients are negative for thoracic LNM, and the blue line represents the assumption that all patients are positive for thoracic LNM

Back to article page